Intellect Neurosciences Inc. (fka ILNS)

[tencoin]

Results: Within the bapineuzumab group, a decrease at end of study compared with baseline was found both for CSF T-tau (–72.3 pg/mL) and P-tau (–9.9 pg/mL). When comparing the treatment and placebo groups, this difference was statistically significant for P-tau (P = .03), while a similar trend for a decrease was found for T-tau (P = .09). No clear-cut differences were observed for CSF Aβ.
Conclusions: To our knowledge, this study is the first to show that passive Aβ immunotherapy with bapineuzumab results in decreases in CSF T-tau and P-tau, which may indicate downstream effects on the degenerative process. Cerebrospinal fluid biomarkers may be useful to monitor the effects of novel disease-modifying anti-Aβ drugs in clinical trials.
Trial Registrations: clinicaltrials.gov Identifier: NCT00112073, EudraCT Identifier: 2004-004120-12, and isrctn.org Identifier: ISRCTN17517446.

LINK:
http://www.ncbi.nlm.nih.gov/pubmed/22473769